Ocular Therapeutix (OCUL) Interest Coverage Ratio: History & Chart

Ocular Therapeutix, Inc.(OCUL)

Biotechnology · Bedford, MA

$7.46+0.21 (+2.95%)

Delayed quote: Oct 6, 2026, 2:45 PM EDT

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Bedford, MA

325 employees

www.ocutx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pravin U. Dugel

View full financials

OCUL Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-22.82x

INTEREST COVERAGE RATIO AVG TTM

-26.59x

INTEREST COVERAGE RATIO AVG 3Y

-17.47x

INTEREST COVERAGE RATIO AVG 5Y

-15.21x

INTEREST COVERAGE RATIO AVG 10Y

-18.91x

INTEREST COVERAGE RATIO AVG 15Y

N/A

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+14.19%

CURRENT VS 3Y AVG

-30.60%

CURRENT VS 5Y AVG

-50.01%

CURRENT VS 10Y AVG

-20.67%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-6.38x

median of 528 covered companies

CURRENT VS SECTOR MEDIAN

-257.96%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Ocular Therapeutix, Inc. (OCUL)	$1.63B	-22.82x	-26.59x	-17.47x	-15.21x
Alphatec Holdings, Inc. (ATEC)vs ›	$1.63B	-3.88x	0.61x	0.61x	0.61x
Septerna Inc (SEPN)vs ›	$1.63B	N/A	N/A	N/A	N/A
ANI Pharmaceuticals, Inc. (ANIP)vs ›	$1.62B	4.05x	2.04x	1.94x	1.94x
Omnicell, Inc. (OMCL)vs ›	$1.61B	2.98x	1.52x	1.52x	6.00x
Kestra Medical Technologies, Ltd. (KMTS)vs ›	$1.61B	-17.85x	N/A	N/A	N/A
uniQure N.V. (QURE)vs ›	$1.61B	-3.03x	41.56x	41.56x	41.56x
Zenas BioPharma, Inc. (ZBIO)vs ›	$1.69B	-28.85x	N/A	N/A	N/A
Stoke Therapeutics, Inc. (STOK)vs ›	$1.57B	-2287.78x	N/A	N/A	N/A
Personalis, Inc. (PSNL)vs ›	$1.70B	-429.55x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Ocular Therapeutix, Inc. (OCUL)

$1.63B

-22.82x

-26.59x

-17.47x

-15.21x

Alphatec Holdings, Inc. (ATEC)vs ›

$1.63B

-3.88x

0.61x

Septerna Inc (SEPN)vs ›

$1.63B

N/A

ANI Pharmaceuticals, Inc. (ANIP)vs ›

$1.62B

4.05x

2.04x

1.94x

Omnicell, Inc. (OMCL)vs ›

$1.61B

2.98x

1.52x

6.00x

Kestra Medical Technologies, Ltd. (KMTS)vs ›

$1.61B

-17.85x

N/A

uniQure N.V. (QURE)vs ›

$1.61B

-3.03x

41.56x

Zenas BioPharma, Inc. (ZBIO)vs ›

$1.69B

-28.85x

N/A

Stoke Therapeutics, Inc. (STOK)vs ›

$1.57B

-2287.78x

N/A

Personalis, Inc. (PSNL)vs ›

$1.70B

-429.55x

N/A

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Ocular Therapeutix, Inc. (OCUL)?

The interest coverage ratio for OCUL stock is -22.82x.

Is Ocular Therapeutix, Inc.'s interest coverage ratio high or low?

The interest coverage ratio of -22.82x is 50% below its 5-year average of -15.21x, around the middle of its 5-year range (-33.61x–-4.83x).

What is the TTM average interest coverage ratio for Ocular Therapeutix, Inc. (OCUL)?

The TTM average interest coverage ratio for OCUL stock is -26.59x.

What is the 3Y average interest coverage ratio for Ocular Therapeutix, Inc. (OCUL)?

The 3Y average interest coverage ratio for OCUL stock is -17.47x.

What is the 5Y average interest coverage ratio for Ocular Therapeutix, Inc. (OCUL)?

The 5Y average interest coverage ratio for OCUL stock is -15.21x.

What is the 10Y average interest coverage ratio for Ocular Therapeutix, Inc. (OCUL)?

The 10Y average interest coverage ratio for OCUL stock is -18.91x.

DATE	INTEREST COVERAGE RATIO
2026-06-30	-29.41x
2026-03-31	-33.61x
2025-12-31	-24.63x
2025-09-30	-22.88x
2025-06-30	-22.43x
2025-03-31	-21.42x
2024-12-31	-16.28x
2024-09-30	-14.27x
2024-06-30	-13.64x
2024-03-31	-7.80x
2023-12-31	-4.83x
2023-09-30	-5.61x
2023-06-30	-10.33x
2023-03-31	-12.75x
2022-12-31	-10.48x
2022-09-30	-11.99x
2022-06-30	-11.74x
2022-03-31	-10.60x
2021-12-31	-10.74x
2021-09-30	-11.78x
2021-06-30	-12.22x
2021-03-31	-12.05x
2020-12-31	-8.31x
2020-09-30	-8.17x
2020-06-30	-10.56x
2020-03-31	-10.17x
2019-12-31	-11.86x
2019-09-30	-14.02x
2019-06-30	-13.28x
2019-03-31	-19.31x
2018-12-31	-46.21x
2018-09-30	-34.94x
2018-06-30	-29.81x
2018-03-31	-27.69x
2017-12-31	-25.95x
2017-09-30	-30.95x
2017-06-30	-39.19x
2017-03-31	-35.38x
2016-12-31	-29.84x
2016-09-30	-21.69x
2016-06-30	-26.57x
2016-03-31	-25.14x
2015-12-31	-25.18x
2015-09-30	-27.52x
2015-06-30	-23.79x
2015-03-31	-14.09x
2014-12-31	-18.54x
2014-09-30	-16.45x
2014-06-30	-23.14x
2014-03-31	-158.72x
2013-12-31	-37.57x
2013-09-30	-36.54x
2013-06-30	-27.93x
2013-03-31	-20.54x

DATE

INTEREST COVERAGE RATIO

2026-06-30

-29.41x

2026-03-31

-33.61x

2025-12-31

-24.63x

2025-09-30

-22.88x

2025-06-30

-22.43x

2025-03-31

-21.42x

2024-12-31

-16.28x

2024-09-30

-14.27x

2024-06-30

-13.64x

2024-03-31

-7.80x

2023-12-31

-4.83x

2023-09-30

-5.61x

2023-06-30

-10.33x

2023-03-31

-12.75x

2022-12-31

-10.48x

2022-09-30

-11.99x

2022-06-30

-11.74x

2022-03-31

-10.60x

2021-12-31

-10.74x

2021-09-30

-11.78x

2021-06-30

-12.22x

2021-03-31

-12.05x

2020-12-31

-8.31x

2020-09-30

-8.17x

2020-06-30

-10.56x

2020-03-31

-10.17x

2019-12-31

-11.86x

2019-09-30

-14.02x

2019-06-30

-13.28x

2019-03-31

-19.31x

2018-12-31

-46.21x

2018-09-30

-34.94x

2018-06-30

-29.81x

2018-03-31

-27.69x

2017-12-31

-25.95x

2017-09-30

-30.95x

2017-06-30

-39.19x

2017-03-31

-35.38x

2016-12-31

-29.84x

2016-09-30

-21.69x

2016-06-30

-26.57x

2016-03-31

-25.14x

2015-12-31

-25.18x

2015-09-30

-27.52x

2015-06-30

-23.79x

2015-03-31

-14.09x

2014-12-31

-18.54x

2014-09-30

-16.45x

2014-06-30

-23.14x

2014-03-31

-158.72x

2013-12-31

-37.57x

2013-09-30

-36.54x

2013-06-30

-27.93x

2013-03-31

-20.54x

Interest Coverage Ratio: -22.82x

OCUL Interest Coverage Ratio

OCUL Average Interest Coverage Ratio Chart

OCUL Current vs Average Interest Coverage Ratio Chart

OCUL Interest Coverage Ratio Metrics

OCUL Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

OCUL Interest Coverage Ratio History

Related Metrics